KRASNO RICHARD M
KRASNO RICHARD M's purchase track record
KRASNO RICHARD M has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/23/2025 | BCDA | $25K | +29.0% | -21.5% | +24.6% |
| 1/29/2024 | OPK | $30K | +21.6% | +40.2% | +10.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
OPKO Health Shares Rise on $722M BioReference Asset Sale. OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.
Transaction History
| BCDA | ▲ Buy | Open Market | 13,123 | $25K | 4/23/2025 | View on chart |
| OPK | ▲ Buy | Open Market | 30,000 | $30K | 1/29/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioCardia Resubmits Helix Catheter Pre-Submission to FDA
BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.
BioCardia Resubmits Helix Catheter Pre-Submission to FDA. BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.